News

Mr Wilke will report directly to Raymond Merk, Datatrak’s CFO and COO, and be integrally involved in the development of the Datatrak eClinical platform. The company also announced

Chemaphor said that it has core expertise in organic chemistry and as a secondary activity, specializes in the synthesis of research chemicals labeled with stable isotopes. The use

Dr Yocum will be responsible for leading the clinical development of soluble ferric pyrophosphate (SFP), the company’s proprietary iron maintenance product currently progressing through a US Phase II

Managed Health Services (MHS), a Medicaid managed care company, serving SCHIP and Hoosier Healthwise members in Indiana engaged SynCare to assist the company in providing comprehensive care and

In collaboration with Avid Radiopharmaceuticals, ProteoTech scientists will utilize ProteoTech’s small molecule platform drug technology to develop new imaging agents that will allow doctors to use PET imaging

ASP2314/ACR-16 represents a novel class for the treatment of schizophrenia and other CNS disorders. In 2005, Astellas obtained rights from Carlsson Research (current Neurosearch) to develop, manufacture and

As Pearl Therapeutics’s new CEO, Mr Karsen brings more than 25 years of experience in the biotechnology and pharmaceutical industries. Most recently, Mr Karsen served as regional president

The financing will allow FlexGen to speed up the development and global commercialization of its FlexArrayer, an instrument that provides researchers with unprecedented freedom in the production of

Prior to joining LabCorp, Dr Brecher served as vice chair of the department of pathology and laboratory medicine at the McLendon Clinical Laboratories, University of North Carolina Hospitals.